Ask AI

CCO Independent Highlights of the 2025 World Conference on Lung Cancer *

Enhance your understanding of novel agents and therapeutic strategies for patients with lung cancers based on data recently presented at the WCLC 2025 and gain expert perspectives on their optimal integration into practice to improve clinical outcomes through certified Medical Minute modules, downloadable capsule summaries, an expert-written ClinicalThought commentary, and a podcast.

Share

Program Content

Activities

IMforte WCLC 2025
Expert Insights From WCLC 2025 on IMforte: Safety Analysis of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2026

Expires: August 23, 2026

ARROS1 WCLC 2025
Expert Insights From WCLC 2025 on ARROS-1: Phase I/II Study of Zidesamtinib for Patients With Advanced ROS1+ NSCLC After Prior ROS1 TKI
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

Expires: August 25, 2026

DeLLphi-303 WCLC 2025
Expert Insights From WCLC 2025 on DeLLphi-303: 1L Maintenance Therapy With Tarlatamab + PD-L1 Inhibitor in Extensive-Stage SCLC
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

Expires: August 25, 2026

FLAURA2 WCLC 2025
Expert Insights From WCLC 2025 on FLAURA2: Final Overall Survival of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

Expires: August 25, 2026

Beamion LUNG 1 WCLC 2025
Expert Insights From WCLC 2025 on Beamion LUNG-1: Phase Ib Study of Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases
Conference Coverage
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Expires: August 26, 2026

5 Capsule Summaries

Activities

IMforte Safety Analysis
IMforte: Expanded Safety Analysis of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

FLAURA2 Final OS
FLAURA2: Final Overall Survival of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

Beamion LUNG 1 Brain Mets
Beamion LUNG-1: Phase Ib Study of Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

ARROS 1
ARROS-1: Phase I/II Study of Zidesamtinib for Patients With Advanced ROS1+ NSCLC After Prior ROS1 TKI
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2025

DeLLphi 303 Maintenance
DeLLphi-303: Updated Phase Ib Results of 1L Maintenance Therapy With Tarlatamab + PD-L1 Inhibitor in Extensive-Stage SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2025

Activities

WCLC 2025 Frontline Lung Cancer Advances
Novel Frontline Maintenance Therapy Approaches and Targeted Therapies in Lung Cancers: Key Data From the 2025 World Conference on Lung Cancer
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: February 16, 2026

Activities

2025 WCLC Highlights
Expert Highlights From the 2025 World Conference on Lung Cancer
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 29, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

*Decera Clinical Education is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.